Mitsubishi UFJ Trust & Banking Corp reduced its holdings in shares of Guardant Health, Inc. (NASDAQ:GH - Free Report) by 11.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 292,972 shares of the company's stock after selling 37,100 shares during the period. Mitsubishi UFJ Trust & Banking Corp owned approximately 0.24% of Guardant Health worth $8,950,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Pier Capital LLC raised its stake in Guardant Health by 45.4% in the 4th quarter. Pier Capital LLC now owns 230,280 shares of the company's stock worth $7,035,000 after acquiring an additional 71,851 shares during the last quarter. Prudential Financial Inc. raised its stake in shares of Guardant Health by 2,235.6% in the fourth quarter. Prudential Financial Inc. now owns 229,870 shares of the company's stock worth $7,023,000 after purchasing an additional 220,028 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Guardant Health by 3.0% during the fourth quarter. Vanguard Group Inc. now owns 12,052,551 shares of the company's stock worth $368,205,000 after purchasing an additional 350,606 shares during the period. Fox Run Management L.L.C. acquired a new stake in shares of Guardant Health during the fourth quarter worth about $369,000. Finally, KLP Kapitalforvaltning AS purchased a new stake in Guardant Health in the fourth quarter valued at approximately $758,000. 92.60% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
Several analysts have recently commented on the stock. Raymond James reaffirmed an "outperform" rating and issued a $59.00 price objective (up from $39.00) on shares of Guardant Health in a report on Friday, February 21st. Piper Sandler increased their price target on Guardant Health from $34.00 to $50.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. Stephens reiterated an "overweight" rating and set a $55.00 price objective on shares of Guardant Health in a research note on Wednesday, March 26th. Scotiabank raised their target price on Guardant Health from $47.00 to $52.00 and gave the stock a "sector outperform" rating in a report on Monday, February 24th. Finally, Morgan Stanley lifted their price target on Guardant Health from $42.00 to $52.00 and gave the company an "overweight" rating in a research report on Thursday, March 6th. Twenty investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $48.95.
Get Our Latest Report on GH
Guardant Health Stock Down 5.2 %
Shares of Guardant Health stock traded down $2.27 on Thursday, hitting $41.22. 280,681 shares of the company were exchanged, compared to its average volume of 2,134,940. Guardant Health, Inc. has a 1-year low of $15.81 and a 1-year high of $50.89. The stock has a market capitalization of $5.09 billion, a price-to-earnings ratio of -11.58 and a beta of 1.50. The company has a 50-day moving average price of $44.65 and a 200 day moving average price of $34.66.
Guardant Health (NASDAQ:GH - Get Free Report) last issued its earnings results on Thursday, February 20th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.15). Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. The company had revenue of $201.81 million during the quarter, compared to analyst estimates of $192.50 million. Research analysts forecast that Guardant Health, Inc. will post -2.9 EPS for the current year.
About Guardant Health
(
Free Report)
Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.
Featured Articles
Before you consider Guardant Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Guardant Health wasn't on the list.
While Guardant Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
